Safer contraception? new pill aims to lower artery risks
NCT ID NCT07536763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial compares a new combined oral contraceptive pill (estetrol-drospirenone) to a standard one (ethinylestradiol-levonorgestrel) in 98 women aged 18-49. Researchers will measure artery function, blood pressure, and metabolic markers over 12 months to see if the new pill has fewer vascular risks. The goal is to find a safer contraceptive option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Estetrol-drospirenone (a new combined oral contraceptive pill)
What this could lead to
If it works, this could show that the new pill is safer for the heart and blood vessels than current options, offering a better choice for contraception.
What could go wrong
This is a small, early-phase trial (98 participants) comparing two pills, not testing a cure. Results may not apply to all women, and the new pill could still carry risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••